Stockreport

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting [Yahoo! Finance]

Imunon, Inc.  (IMNN) 
PDF Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) [Read more]